January 2026 in “International Journal of Women s Health” This study found that a nomogram prediction model based on clinical characteristics, bone metabolism, and ovarian function can effectively predict the treatment response to long-acting GnRHa in girls with idiopathic central precocious puberty.
3 citations
,
October 2024 in “Advances in Therapy” In this study, Chinese children with central precocious puberty receiving 6-monthly injections of triptorelin showed luteinizing hormone suppression and slowed development of sexual characteristics over 12 months, without severe adverse events, suggesting it may be an effective treatment option for this population.
August 2020 in “Nigerian journal of paediatrics” This case report describes a 24-month-old girl from Nigeria with idiopathic precocious puberty, emphasizing the financial barriers to necessary treatment in developing countries.
34 citations
,
May 1987 in “European Journal of Pediatrics” This study concluded that Buserelin can effectively inhibit gonadal activity in children with central precocious puberty over 18 months, potentially improving final height predictions with prolonged treatment.
January 2024 in “Frontiers in endocrinology” This study found that women treated with GnRHa for central precocious puberty had a higher prevalence of polycystic ovary syndrome in adulthood compared to those with isolated premature thelarche.